Carregant...
A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability
Gemcitabine (Gem) is a standard first-line treatment for pancreatic cancer (PC). However, its chemotherapeutic efficacy is hampered by various limitations such as short half-life, metabolic inactivation, and lack of tumor localizing. We previously synthesized a lipophilic Gem derivative (Gem formyl...
Guardat en:
| Publicat a: | Acta Pharmacol Sin |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Singapore
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6888841/ https://ncbi.nlm.nih.gov/pubmed/31015736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-019-0227-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|